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Introduction: Understanding the epidemiology of cardiovascular disease (CVD) related
comorbidity is a key strategy for improving the outcomes of patients with cancer.
Therefore, this study aimed to assess the distribution of cardiovascular comorbidities
and cardiovascular risk factors (CVRF) among five cancer sites.
Methods: This is a single-centered, cross-sectional study performed in Dalian, China.
Between 2008 and 2018, all newly diagnosed cancer in the First Affiliated Hospital of
Dalian Medical University, China were screened. Clinical data were extracted from a
comprehensive electronic health record system.
Results: 35861 patients with lung, colorectal, gastric, breast, and thyroid cancer
were collected retrospectively. The most prevalent CVDs in descending order were
hypertension (21.9%), followed by coronary heart disease (6.5%), atrial fibrillation (2.9%),
and heart failure (1%). The prevalence of hypertension significantly varies between lung
(21.3%), colorectal (27.3%), gastric (22.5%), breast (16.7%), and thyroid cancer (22.4%)
(P < 0.001). CVRF varies with cancer sites. Age, sex, total cholesterol, triglyceride,
low-density lipoprotein cholesterol, systolic blood pressure, smoking, alcohol use, and
diabetes mellitus (DM) are common risk factors associated with CVD at different cancer
sites. The association between DM and presence of CVD was strong in breast (odds ratio
[OR] = 4.472, 95% confidence interval [CI]: 3.075–6.504, P < 0.001), lung (OR = 3.943;
95% CI: 3.270–4.754, P < 0.001), colorectal (OR = 3.049; 95% CI: 2.326–3.996,
P < 0.001), and gastric (OR = 2.508; 95% CI: 1.927–3.264, P < 0.001) cancer.
Conclusion: Cancer patients had a significant burden of CVD and increased CVRF.
The prevalence of CVRF and CVD comorbidity differ for cancer types. DM remains
significantly associated with CVD at different cancer sites except for thyroid cancer.
Keywords: cancer, cardiovascular diseases, risk factors, hypertension, diabetes mellitus
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Data Source and Study Population

INTRODUCTION

Data for this analysis were obtained from the YiDuloud
Electronic Medical Surveillance Network Database (YEMSND).
The following patients were excluded from the present study:
those without a cancer diagnosis (n = 5,542,453) and those
with a pre-existing diagnosis of cancer (n = 1,578). Finally, a
total of 35,861 participants were included in the data analysis.
Figure 1 describes a brief overview of the selection of study
participants. Institutional review board approval was obtained at
FAHDMU. The requirement for informed consent was waived
and all procedures listed here were carried out in compliance with
Helsinki declaration guidelines.

Cancer is a serious disease that contributes significantly to
mortality and morbidity in the global population (1). According
to the earlier evidence, nearly half of all cancer deaths are
attributed to non-cancer causes, and cardiovascular disease
(CVD) is the leading cause of such deaths (2). There are also
complex causal relationships between cancer and CVD, and
each of them may be caused by, or be a complication of, one
or both of the other diseases (3). The significant advancement
in cancer management led to a substantial increase in cancer
survivors (4). However, this spectacular increase in new cancer
therapies (conventional chemotherapy and targeted therapy) is
often reported to increase the risk of cardiovascular damage, such
as left ventricular dysfunction or heart failure (HF), hypertension
(HTN), and arrhythmias (5).
Common biological pathways between CVD and cancer have
been described previously. It is well-established that cardiac risk
factors have major influences on cancer. The risk intensified in
those with diabetes mellitus (DM), dyslipidemia, and obesity
(6), suggesting that these cardiovascular risk factors (CVRF) are
important features that influence incidence rates of both cancer
and CVD. Of note, risk estimation is of crucial importance to
recognize cancer patients who are at high risk for CVD; therefore,
high-risk patients should be referred to screening for CVD
and undergo interventions if indicated to decrease the burden
of CVD.
To our knowledge, few studies have reported the prevalence
and distribution of CVD among different types of cancer.
Prior studies that focused on defining the most common
comorbidities in adults with cancer have either used a
small sample size or limited data without stratification by
cancer type (7–9). A substantial number of cancer and
CVD cases are attributable to DM (10–12), whereas the
relationship between DM and CVD in cancer patients was
rarely reported. Therefore, the goal of this study was to (1)
assess the distribution of CVD comorbidities and analyze
the associated CVRF among different sites of cancer (lung,
colorectal, gastric, breast, and thyroid) and (2) estimate the
effect of DM interaction with CVD comorbidities in different
cancer sites.

Clinical Measurements and Definition of
Explanatory Variables
Demographic characteristics, major CVD risk factors, lifestylerelated data, and CVD comorbidities were ascertained from
electronic health records by trained health professionals.
Clinical measurements, including fasting glucose level, serum
concentrations of triglycerides, total cholesterol (TC), highdensity lipoprotein cholesterol (HDL-c), and low-density
lipoprotein cholesterol (LDL-c) were retrieved. Dyslipidemia was
defined as the combination of TC of at least 240 mg/dl, LDL-c
of at least 160 mg/dl, and HDL-c of less than 40 mg/dl (13).
DM was defined as, fasting blood glucose (FPG) ≥7.0 mmol/L, a
self-reported history of DM or current diabetes treatment (14).
Smoking was defined as current smoking status or a lifetime
consumption of more than 100 cigarettes as described in existing
studies (15).

Definition of Cardiovascular Comorbidity
We considered CVD as co-morbidities when the cancer was
first diagnosed during hospitalization. HTN was characterized
as systolic blood pressure (SBP) at ≥140 mmHg and/or diastolic
blood pressure (DBP) at ≥90 mmHg or a self-reported history of
HTN with the current use of antihypertensive drugs. Coronary
heart disease (CHD) was defined based on the presence of either
angina or coronary artery stenosis of 50% evidenced by medical
records (16). HF was defined based on the presence of symptoms
of HF and evidence of at least one echocardiographic abnormality
(17). Patients were diagnosed with atrial fibrillation (AF) if they
met any of the following criteria: (1) AF pattern in baseline 12lead electrocardiogram (ECG) screening or (2) AF episodes in
24-hour single-lead ECG recording or Holter (18). We defined
the first signs of AF during hospitalization as the incident AF
cases. Two cardiologists independently performed and read all
ECGs to confirm the cases of AF.

METHODS
Study Design
This is a single-centered, retrospective cross-sectional study
conducted at the First Affiliated Hospital of Dalian Medical
University (FAHDMU). Records of patients hospitalized at
FAHDMU between 30th May 2008 and 30th September 2018
were retrieved for this study. The statistics department
of FAHDMU was contacted to identify the five most
common cancer diagnoses at FAHDMU in the last decade.
Based on the incidence of respective cancer diagnoses
in the database, histologically confirmed lung, colorectal,
gastric, breast, and thyroid cancer were included for
this study.

Frontiers in Cardiovascular Medicine | www.frontiersin.org

Statistical Analysis
All analyses were performed using SPSS software version
24.0 (SPSS, Chicago, Illinois, USA). Continuous variables were
presented using the mean ± standard deviation (SD), whereas
categorical data were expressed using frequency (percentage).
Statistical significance of differences for categorical variables was
tested using χ2 (chi-square). Comparisons between continuous
data for subgroups with and without CVD were conducted
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FIGURE 1 | A brief overview of the selection of study participants.

The comparison of demographic and clinical variables
between cancer patients with and without CVD is presented in
Table 1. Overall, 25.15% of the cancer patients were affected by at
least one type of CVD. Those with CVD were older than the nonCVD group (P < 0.001). Also, those with CVD had a higher mean
SBP and DBP than the non-CVD group (P < 0.001). The rates of
dyslipidemia and DM were significantly higher in the CVD group
compared with the non-CVD (P < 0.001).
As shown in Supplementary Table 1, there was a statistically
significant difference in the prevalence of smoking between
the non-CVD and CVD groups in lung cancer patients (25.7
vs. 29.1%, P < 0.001). Similarly, alcohol consumption was
significantly higher in the CVD group compared with their
counterparts in lung cancer and thyroid cancer patients, but
there were no significant differences in the other types of cancers.
Interestingly, HDL-c level was lower in the CVD group compared
with those without CVD, except for gastric cancer (45.16 vs.
44.93, P > 0.05).

using the independent sample t-test. Binary logistic regression
analysis was employed to estimate the odds ratio (OR) and 95%
confidence interval (CI) for CVD and CVRF associated with the
cancers of different sites. The logistic linear regression analysis
was adjusted for the targeted CVD type, age, gender, alcohol use,
cigarette status, triglycerides, SBP, DBP, HDL-c, LDL-c and DM.
Further, we ran a gender-specific analysis to examine the effect of
gender on the relationship between CVD types and the presence
of cancer at different sites. Statistical significance was defined as
P-value <0.05.

RESULTS
Baseline Characteristics
Among the 5,579,892 hospitalized patients, a total of 35,861
cancer patients (lung cancer = 15,951, colorectal cancer = 6,429,
gastric cancer = 6,253, breast cancer = 5,677, and thyroid
cancer = 1,551) were selected in the final analysis. The mean
±SD ages of cancer patients with CVD and without CVD were
69.12 ± 9.89 and 60.30 ± 12.30, respectively. In total, 4,459 of
the 18,737 women had CVD, which accounted for 23.8% of the
female population whereas 26.6% of the male population had
CVD (P < 0.001).

Frontiers in Cardiovascular Medicine | www.frontiersin.org

Cardiovascular Diseases Prevalence
Among Cancer Patients
As shown in Figure 2, the prevalence of comorbid CVD varies
between different types of cancer. Patients with colorectal cancer
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TABLE 1 | Baseline characteristics of the participants, (N = 35,861).
Variables

No-CVD 26,843 (74.85%)

CVD 9,018 (25.15%)

P
<0.001

Age (years)

60.30 ± 12.30

69.12 ± 9.89

Female, N (%)

14,278 (53.2%)

4,459 (49.4%)

<0.001

SBP (mmHg)

123.84 ± 20.66

135.04 ± 17.77

<0.001

DBP (mmHg)

76.38 ± 9.664

79.59 ± 10.90

<0.001

LDL (mg/dl)

106.05 ± 30.34

101.25 ± 33.20

<0.001

HDL (mg/dl)

48.07 ± 27.13

44.88 ± 27.25

<0.001

269 (4.1%)

186 (4.4%)

<0.001

LDL ≥ 160 (mg/dl)
HDL < 40 (mg/dl)

1,948 (30.0%)

1,694 (40.0%)

<0.001

Triglyceride (mg/dl)

114.80 ± 71.70

124.98 ± 77.87

<0.001

Dyslipidemia (%)
Total Cholesterol (mg/dl)
Total Cholesterol ≥240 (mg/dl)

2581 (39.7%)

2,034 (48.0%)

<0.001

184.89 ± 44.42

175.58 ± 46.55

<0.001

647 (9.9%)

364 (8.6%)

0.019

Smoking N (%)

4,902 (19.0%)

1,910 (21.4%)

<0.001

Alcohol N (%)

2,805 (11.1%)

1,153 (13.2%)

<0.001

Diabetes mellitus, N (%)

1,502 (5.6%)

2,636 (29.2%)

<0.001

Serum uric acid (umol/l)

317.91 ± 100.32

347.71 ± 119.42

<0.000

Hyperuricemia, N (%)

3,207 (13.1%)

1,775 (21.7%)

<0.000

β-blocker use, N (%)

1,100 (4.1%)

2,203 (24.4%)

<0.000

CCB use, N (%)

2,496 (9.3%)

4,102 (45.5%)

<0.000

2,427 (9%)

2,049 (22.7%)

<0.000

Diuretic use, N (%)

CVD, cardiovascular disease; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; CCB,
Calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

(4.1%), followed by lung (2.9%) and gastric (2.9%) cancer. The
rates of coronary heart disease in lung, colorectal, gastric, and
thyroid cancer were 6.6, 7.2, 6.7, and 6.6%, respectively without
significant intergroup differences. The distribution of comorbid
CVD according to cancer types is presented in Table 2.

Sex-Based Comparison of Cardiovascular
Disease Comorbidity
The overall rate of cancer patients with CVD was significantly
higher amongst male patients (P < 0.001). Likewise, male
patients with colorectal and gastric cancer had a higher
prevalence of HTN comorbidities than their female counterparts
(P < 0.001). Similarly, the proportion of CHD and AF in lung
cancer patients was significantly higher in men in comparison
to women (P < 0.01). Also, there was a statistically significant
difference in AF rate between men and women with thyroid
cancer (1.6 vs. 3.7%, P < 0.05). More detailed information on
the gender differences in comorbid CVD according to cancer
categories is presented in Figure 3.

FIGURE 2 | Distribution of CVD among different cancers. CVD, cardiovascular
disease.

had the highest prevalence of CVD comorbidities (31.0%),
followed by patients with gastric (26.8%), lung (24.6%), thyroid
(24.5%), and breast (18.5%) cancer.
The most common CVDs in descending order are HTN
(21.9%), followed by CHD (6.5%), AF (2.9%), and HF (1%).
The prevalence of HTN varies between lung (21.3%), colorectal
(27.3%), gastric (22.5%), breast (16.7%), and thyroid cancer
(22.4%) with P < 0.001.
The highest and the lowest prevalence of CHD was observed
among patients with colorectal (7.2%) and breast (4.9%) cancer.
The prevalence of AF was the highest in colorectal cancer

Frontiers in Cardiovascular Medicine | www.frontiersin.org

Risk Factors of CVD in Selected Cancer
We evaluated the risk factors associated with CVD among
patients stratified by cancer categories (Table 3). The findings of
the present study demonstrated a positive association between
DM and the presence of CVD in all studied cancer except for
thyroid cancer. The association between DM and presence of
CVD was strong in breast (OR = 4.472, 95% CI: 3.075–6.504,
P < 0.001), lung (OR = 3.943; 95% CI: 3.270–4.754, P < 0.001),
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TABLE 2 | Prevalence of cancer patients with CVDs.
All

Lung

Colorectal

Gastric

Breast

Thyroid

(n = 35,681)

(n = 15,951)

(n = 6,429)

(n = 6,253)

(n = 5,677)

(n = 1,551)

CVD, N (%)

9,018 (25.1)

3,919 (24.6)

1,996 (31.0)

1,675 (26.8)

1,048 (18.5)

380 (24.5)

< 0.001

HTN, N (%)

7,848 (21.9)

3,390 (21.3)

1,755 (27.3)

1,406 (22.5)

950 (16.7)

347 (22.4)

< 0.001

CHD, N (%)

2,320 (6.5)

1,054 (6.6)

461 (7.2)

421 (6.7)

281 (4.9)

103 (6.6)

< 0.001

AF, N (%)

1,041 (2.9)

470 (2.9)

263 (4.1)

182 (2.9)

93 (1.6)

33 (2.1)

< 0.001

HF, N (%)

345 (1.0)

160 (1.0)

76 (1.2)

54 (0.9)

45 (0.8)

10 (0.6)

0.110

P

HTN, hypertension; AF, atrial fibrillation; CHD, coronary heart disease; HF, heart failure.

FIGURE 3 | Comparison of CVD comorbidities between men and women according to cancer categories. HTN, hypertension; HF, heart failure; AF, atrial fibrillation;
CHD, coronary heart disease; *P < 0.05, ***P < 0.001.

DISCUSSION

colorectal (OR = 3.049; 95% CI: 2.326–3.996, P < 0.001), and
gastric (OR = 2.508; 95% CI: 1.927–3.264, P < 0.001) cancer.
In the multivariate model, the logistic regression analysis
presented that old age, high levels of triglycerides, and increased
levels of SBP were independent risk factors for lung, colorectal,
and gastric cancer. We also observed smoking (OR = 1.917; 95%
CI: 1.300–2.827, P < 0.001) was independently associated with
colorectal cancer. Similarly, breast cancer patients with increased
DBP had higher rates of CVD. Likewise, being female was
associated with a lower prevalence of CVD in lung (OR = 0.850;
95% CI = 0.733–0.985, P < 0.05) and colorectal (OR = 0.719,
95% CI 0.555–0.931, P < 0.05) cancer.
Frontiers in Cardiovascular Medicine | www.frontiersin.org

There are three major findings to the present study: (1) cancer
patients carry a significant burden of CVD-related comorbidities;
(2) the prevalence of selected CVD (HTN, AF, HF, and CHD)
varies by cancer type; (3) HTN is the most common CVD
comorbidity among all studied cancers while DM is the most
common CVRF.
The present study showed that cancer patients carry a high
CVD burden. According to a recent multicentered study, 18.0%
of the cohort were affected by at least one type of CVD with a
mean age of 55 years at cancer diagnosis (8). The relatively high
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TABLE 3 | Cardiovascular risk factors among the different cancer sites.
Cancer type
Lung

Colorectal

Female

OR

95% C.I.

P

0.075

4.648

0.85

0.733–0.985

0.031

0.058

0.004

265.102

1.06

1.052–1.067

< 0.001

Tch

−0.004

0.001

22.268

0.996

0.994–0.998

< 0.001

TG

0.002

0.001

16.984

1.002

1.001–1.003

< 0.001

SBP

0.034

0.002

234.633

1.035

1.030–1.039

< 0.001

DM

1.372

0.095

206.362

3.943

3.270–4.754

< 0.001

Age

0.052

0.006

87.841

1.054

1.042–1.065

< 0.001

Tch

< 0.001

−0.007

0.001

26.195

0.993

0.990–0.996

SBP

0.039

0.004

109.177

1.04

1.032–1.048

< 0.001

DM

1.115

0.138

65.249

3.049

2.326–3.996

< 0.001

0.132

6.238

0.719

0.555–0.931

0.013

0.198

10.792

1.917

1.300–2.827

< 0.001

Alcohol

Thyroid

Wald

−0.163

Female

Breast

S.E.

Age

Smoke
Gastric

B

−0.33
0.651

0.218

5.452

0.601

0.392–0.921

0.02

Age

0.048

0.005

91.369

1.049

1.039–1.059

< 0.001

TG

0.005

0.001

29.165

1.005

1.003–1.007

< 0.001

SBP

0.039

0.003

141.811

1.04

1.033–1.047

< 0.001

DM

0.919

0.134

46.817

2.508

1.927–3.264

< 0.001
< 0.001

−0.51

Tch

−0.009

0.001

44.989

0.991

0.989–0.994

Age

0.089

0.007

154.198

1.094

1.078–1.109

< 0.001

Tch

−0.023

0.005

21.172

0.977

0.968–0.987

< 0.001

TG

0.002

0.001

6.517

1.002

1.001–1.004

< 0.001

DM

1.498

0.191

61.462

4.472

3.075–6.504

< 0.001

LDL

0.024

0.007

11.809

1.024

1.010–1.038

< 0.001

DBP

0.015

0.007

4.384

1.015

1.001–1.029

0.036

Age

0.081

0.012

42.353

1.085

1.058–1.112

0.001

HDL

−0.008

0.005

2.184

0.992

0.982–1.003

0.139

TG

0.005

0.002

10.691

1.005

1.002–1.008

0.001

SBP

0.046

0.009

26.888

1.047

1.029–1.066

0.001

−0.008

0.003

5.379

0.992

0.986–0.999

0.020

Tch

SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; Tch, total cholesterol; TG, triglyceride;
SE, standard error; OR, odds ratio; CI, confidence interval. Adjusted for age, gender, cigarette status, alcohol use, triglycerides, SBP, DBP, HDL and LDL.

between HTN and DM, it is important to keep in mind the
increased CVD risk in the management of cancer patients. A
metanalysis by Zhu et al. indicated that DM patients will have
five years shorter in their survival from the colorectal, colon, and
rectal cancers compared to patients without DM (23). Hence, our
result indicates that a holistic control strategy of CVRF is not
inferior to a DM control strategy in preventing the risk of CVD
in cancer patients.
HTN is the most common form of CVD and it is linked
to other major CVD complications (24). In our study, the
distribution of HTN was significantly higher than that of other
cardiovascular comorbidities in the studied cancers. Recent
meta-analyses of observational studies have reported higher
risks for colorectal, prostate, and breast cancer in hypertensive
compared with normotensive individuals (25–27). However, the
association between HTN and cancer is still not clear. It is
hypothesized that the two conditions share common risk factors
and mechanisms of pathogenesis. For instance, it has been
speculated that predisposition to cancer is aggravated by chronic
inflammation (28) and lipid peroxidation (29). Also, another
possible biological explanation that links HTN and cancer may

prevalence of comorbidity (25.15%) in our study may be related
to the older mean age of 69.12 ± 9.89 at diagnosis. It is supported
by a study by Giovannucci et al. (19), which found that 78%
of new cancers were related to aging (≥55 years old). We also
focused on a limited number of CVD comorbidity, which could
also contribute to the difference in the prevalence of CVD.
In this study, cancer patients of lung, colorectal, gastric,
breast, and thyroid suffered from a high prevalence of CVD. We
found that among the studied cancers, colorectal cancer had the
highest prevalence of cardiovascular comorbidities. Colorectal
cancer is the third most commonly diagnosed cancer around the
world with a male predominance (20). Given the prevalence of
colorectal cancer and CVD, in addition to the increased CVD risk
in males, it is not surprising to find a high coexistence between
CVD and colorectal cancer.
Also, results from the current study demonstrated that
colorectal cancer patients diagnosed with DM had an increased
risk for HTN, AF, and CHD. It has been previously demonstrated
that HTN increases the risk of colorectal cancer (21, 22).
Considering the strong relationship between HTN and other
CVD such as AF and CHD, as well as the strong inter-relationship

Frontiers in Cardiovascular Medicine | www.frontiersin.org
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CONCLUSION

be via angiogenic factors. Hypertensive subjects have been found
to have an increased concentration of serum vascular endothelial
growth factor (VEGF), a hormone that plays a critical role in the
promotion of angiogenesis in tumors (30). Further, experimental
studies have implicated a potential role of the renin-angiotensinaldosterone system (31). Recently, blockade of the angiotensin II
type 1 receptor in mice was found to attenuate the growth and
metastatic potential of renal cell carcinoma (32).
In general, CVD and cancer are viewed as two distinct disease
entities. However, CVD and cancer interact on multiple levels,
sharing common causal mechanisms and epidemiologic risk
factors (3). The findings of the present study demonstrated a
positive association between DM and the presence of CVD in all
studied cancer except for thyroid cancer. It has been previously
demonstrated that type 2 DM patients embrace a significantly
higher risk of cancer (33). It is uncertain whether the relationship
between DM and cancer is direct or indirect given the common
risk factors Earlier evidence documented that the duration of
DM is an important factor in the progress of cancer among
insulin-using type 2 DM patients (34). However, the pathogenic
mechanisms remain unclear. Given the burden of CVD and
cancer tends to increase in advanced age groups, the combination
of the duration of DM along with increased age may confound
the association between DM and cancer. The mechanisms of such
increased cancer risk in diabetic patients may be linked with
hyperinsulinemia, increased insulin resistance, inflammation,
and oxidative stress (35).

In conclusion, this cross-sectional study confirmed that cancer
patients had a significant burden of CVD and increased CVRF.
Prevalence of CVRF and CVD comorbidity differ for cancer type.
Among the studied cancers, colorectal cancer had the highest
prevalence of cardiovascular comorbid conditions. DM remained
a major risk factor for CVD comorbidity at different cancer sites
except for thyroid cancer. Medical practitioners should enhance
the delivery of high-quality cardiovascular care for patients with
cancer to control their cardiovascular risk and provide routine
cardiovascular monitoring.
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accurate measurements. Detailed data on lifestyle, blood
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also available, allowing adjustment for potential confounders.
However, the present study has several limitations. First of all,
the blood pressure and lipid panel were measured only at a onetime point. This was a single-center cross-sectional study and
was subject to inherent limitations associated with cross-sectional
data, such as the inability to establish cause-effect relationships.
Also, the present study is a single-centered study in China,
which can limit its generalizability given the effect of lifestyle and
ethnicity on CVD risk. Consequently, the results of the present
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Moreover, the lack of continuous ECG monitoring means that
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non-cancer participants.
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